Haleon to Set Up First India Manufacturing Facility with ₹2,000 Crore Investment.

Consumer healthcare major Haleon has announced plans to invest about ₹2,000 crore (£175 million) to establish its first manufacturing facility in India, underscoring the country's importance as one of its fastest-growing markets.

The company will set up a greenfield manufacturing site at Pithampur in Madhya Pradesh, focused on oral care products. The facility is expected to become operational by 2029-30 and will cater to domestic demand while also serving export markets across Asia over time.

Describing the project as Haleon's largest investment in India, Chief Executive Officer Brian McNamara said the facility will strengthen the company's supply chain capabilities and reduce dependence on imports.

“This will be our largest investment in India, where we see significant potential for the future. It will strengthen our supply chain, our resilience and our agility, while reducing the reliance on imports into India,” McNamara said.

He added that the investment would enable the company to respond more quickly to local consumer needs, particularly in the oral health segment, which has been witnessing consistent double-digit growth. The project also aligns with Haleon's India growth strategy centred on innovation-led premiumisation.

Haleon's portfolio in India includes brands such as Sensodyne, Parodontax, Pronamel, Centrum, Eno, Otrivin, Iodex and Crocin. India is currently the second-largest market globally for Sensodyne, the company's flagship oral care brand.

The proposed facility is expected to bolster Haleon's manufacturing footprint in the country and support its long-term growth ambitions in both domestic and regional markets.